About 10 results found for searched term "AKT-IN-14" (0.295 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M43366 | AKT-IN-14 free base | Akt |
| AKT-IN-14 free baseis a potent AKTinhibitor with the IC50 values of <0.01 nM, 1.06 nM and 0.66 nM for AKT1, AKT2, AKT3, respectively. | ||
| M43367 | AKT-IN-14 | Akt |
| AKT-IN-14 is a potent AKTinhibitor with the IC50 values of <0.01 nM, 1.06 nM and 0.66 nM for AKT1, AKT2, AKT3, respectively. | ||
| M1749 | Gefitinib | EGFR/HER2 |
| ZD-1839, Iressa | ||
| Gefitinib (ZD1839) is an EGFR tyrosine kinase and Akt phosphorylation inhibitor. Gefitinib significantly down-regulates CD47 expression and increases DC phagocytosis in non-small cell lung cancer cells such as PC9, H1437 and H1573. Gefitinib combined with CD47 antibody can enhance the phagocytosis of macrophages. | ||
| M2132 | A-674563 | Akt |
| A-674563 is a potent, orally available PKB/Akt inhibitor with an IC50 of 14 nM. | ||
| M11229 | Miransertib hydrochloride | Akt |
| ARQ-092 hydrochloride | ||
| Miransertib hydrochloride (ARQ-092 Hydrochloride) is a potent, orally active, selective and allosteric Akt inhibitor with an IC50 of 2.7 nM for Akt1, Akt2, and Akt3, respectively. 14 nM and 8.1 nM. Miransertib hydrochloride is an effective inhibitor of AKT1-E17K mutant protein, and can be used in the study of PI3K/ AkT-driven tumors and Proteus syndrome. Miransertib hydrochloride effectively inhibited Leishmania. | ||
| M11259 | Cefminox sodium | Antibiotic |
| Meicelin, MT-141 | ||
| Cefminox Sodium (MT-141) is a semi-synthetic cephalomycin with a broad spectrum of antibacterial activities. Cefminox sodium (MT-141) is a dual agonist of prostacyclin receptor and PPARγ, which can up-regulate cAMP production and PTEN expression, and inhibit Akt/mTOR signaling pathway. Cefminox sodium (MT-141) can inhibit pulmonary hypertension. | ||
| M22521 | ZINC00640089 | Akt |
| ZINC00640089 is a specific Lipocalin-2 (LCN2) inhibitor. ZINC00640089 inhibits cell proliferation, cell viability and reduces AKT phosphorylation levels in SUM149 cells. | ||
| M27987 | CC214-2 | mTOR |
| CC214-2 is an oral active and selective mTOR kinase inhibitor. CC214-2 targets to both of mTORC1 (pS6) and mTORC2 (pAktS473). CC214-2 induces autophagy, which is a potential target for host-directed therapy (HDT) in tuberculosis. CC214-2 exhibits synergistic bactericidal and sterilizing activity agasinst tuberculosis (TB), and shortens the treatment duration. CC214-2 also inhibits Rapamycin-resistant signaling and the growth of glioblastomas in vitro and in vivo. | ||
| M29562 | MS98 | PROTAC |
| MS98 is a potent and selective PROTAC AKT degrader. MS98 depletes cellular total AKT (T-AKT) with the DC50 value of 78 nM. MS98 binds to AKT1, AKT2, and AKT3 with Kds of 4 nM, 140 nM, and 8.1 nM, respectively. | ||
| M29563 | MS143 | Akt |
| MS143 is a potent AKT degrader (DC50=46 nM and GI50=0.8 µM in PC3 cells). MS143 induces rapid and robust AKT degradation in a concentration- and time-dependent manner via hijacking the ubiquitin-proteasome system. MS143 can suppress cancer cell growth. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
